Jak leczymy pacjenta z nowo rozpoznaną amyloidozą łańcuchów lekkich pośredniego ryzyka? Rola doksycykliny w terapii amyloidozy z zajęciem serca

Abstract

Treatment of patients with light chain amyloidosis (AL amyloidosis) is a challenge in routine clinical practice. Although deep and durable hematologic response is crucial for the success of the therapy, in this group of patients the proper conduct of supportive care becomes particularly important. Because AL amyloidosis is an interdisciplinary disease entity, the therapeutic process should be coordinated by an interdisciplinary team consisting of a hematologist, cardiologist, nephrologist, gastroenterologist, neurologist and clinical dietician. In this paper, we present a strategy for treating a patient with a newly diagnosed systemic intermediate-risk AL amyloidosis with cardiac involvement in the Department of Hematology of the Institute of Hematology and Transfusion Medicine in Warsaw, in which, apart of standard chemotherapy, doxycycline was used.